Form 4: Director Kaushal Boosts TOI Stake with RSU Grants

The Oncology Institute Director Mohit Kaushal acquired 91,049 shares of common stock through restricted stock unit grants on November 20, 2025.

Summary

• Mohit Kaushal, a Director of The Oncology Institute, Inc. (TOI), acquired a total of 91,049 shares of common stock on November 20, 2025.
• This acquisition was through two separate grants of Restricted Stock Units (RSUs), with a transaction price of $0 per share.
• The first grant involved 50,926 shares, which are scheduled to vest in full on the Issuer's 2026 annual stockholder meeting date, contingent on continued service.
• The second grant involved 40,123 shares, which were fully vested upon grant.
• Following these transactions, Mohit Kaushal beneficially owns 268,302 shares of The Oncology Institute's common stock.

Sentiment

Score: 7

Explanation: The acquisition of additional shares by a director, even through restricted stock unit grants, generally signals management's continued alignment with shareholder interests and confidence in the company's long-term prospects. The immediate vesting of a portion of the shares adds to this positive sentiment.

Positives

• Increased ownership by a director, indicating alignment of interests with shareholders.
• A portion of the RSUs (40,123 shares) were fully vested upon grant, providing immediate equity to the director.

Negatives

• No immediate cash outlay for the director, as these are RSU grants at a price of $0, rather than open market purchases.
• A significant portion of the acquired shares (50,926) are restricted and subject to future vesting conditions.

Risks

• The vesting of 50,926 shares is subject to continued service with the Issuer through the 2026 annual stockholder meeting date, meaning the director could forfeit these shares if service ceases prematurely.
• The value of the acquired shares is dependent on the future stock price of The Oncology Institute, Inc., exposing the director to market fluctuations.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction, beyond the vesting schedule of the granted restricted stock units.

Industry Context

This Form 4 filing, detailing an insider's equity acquisition, is a routine disclosure in the public markets. It reflects a director's compensation structure and personal investment in the company, which can be viewed as a positive signal of confidence in the company's future, common across various industries, including healthcare.

Stakeholder Impact

• Shareholders: Increased director ownership may be viewed positively, aligning management interests with shareholder value.
• Employees: The use of equity compensation like RSUs is a common practice to incentivize and retain key personnel.

Next Steps

• The 50,926 restricted stock units are expected to vest in full on The Oncology Institute's 2026 annual stockholder meeting date, subject to Mohit Kaushal's continued service.

Key Dates

Recommendation

This Form 4 filing indicates a director's increased equity stake through restricted stock unit grants, which is a positive signal of alignment and confidence. However, it does not provide sufficient financial or operational data to warrant a change in investment recommendation. Investors should consider this information in conjunction with the company's broader financial performance and strategic outlook.

Keywords

The Oncology Institute, TOI, Mohit Kaushal, Director, Form 4, Restricted Stock Units, RSU, Insider Trading, Stock Ownership, Equity Compensation